Skip to content

Allergan Receives FDA Approval for ACUVAIL™ Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery

Allergan, Inc. (NYSE: AGN) today announced that the United States Food and Drug Administration (FDA) has approved ACUVAIL™ (ketorolac tromethamine ophthalmic solution) 0.45%, an advanced, preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery.

Read more here  >

Allergan Receives FDA Approval for ACUVAIL™ Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery

Global in reach. Specialized in focus.

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.

In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.

We are pleased to offer a number of leading products, including: BOTOX® (onabotulinumtoxinA), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® family of dermal fillers, and the LAP-BAND® Adjustable Gastric Banding System. Throughout our Web site you can learn more about these and our full portfolio of products.

AGN NYSE
58.62 (-0.03)
Volume 1,228,800

GLOBAL LOCATIONS

Learn about our worldwide locations.

  

NEWS & EVENTS

10.29.09Allergan Reports Third Quarter 2009 Operating Results
10.23.09Allergan Announces Victory in Brimonidine Patent Infringement Case
10.01.09Allergan Files Federal Lawsuit to Allow It to Share Relevant Information with the Medical Community on the Safe Use of BOTOX(R) for Common Therapeutic Off-Label Treatments
More news